Technavio
Announces the Publication of its Research Report Global Lung Cancer
Therapeutics Market 2016-2020
Technavio recognizes the following companies as the key players in the global lung cancer therapeutics market: F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, and Celgene.
Other Prominent Vendors in the market are: Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Xcovery.
Commenting on the report, an analyst from Technavios team said: The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact on the market. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, nanotechnology approach could radically lower this requirement, allowing much earlier diagnosis or treatment regimes.”
Technavio recognizes the following companies as the key players in the global lung cancer therapeutics market: F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, and Celgene.
Other Prominent Vendors in the market are: Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Xcovery.
Commenting on the report, an analyst from Technavios team said: The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact on the market. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, nanotechnology approach could radically lower this requirement, allowing much earlier diagnosis or treatment regimes.”
Know more about sample report: https://marketreportscenter.com/reports/470096/global-lung-cancer-therapeutics-market-2016-2020#
According to
the report, the market has been witnessing an increased demand for immune-based
therapies such as checkpoint inhibitors. There are various types of checkpoint
inhibitors that target different checkpoints on immune cells. These treatments
work by allowing to mount a stronger and effective attack against lung cancer. The
traditional chemotherapy approach involves the destruction of cancerous cells
as well as nearby benign cells. This will create a lot of side effects and
affects the patient compliance.
Further, the report states that the growing popularity of alternative therapeutics are expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking for alternative therapeutics. The increased demand for these therapies is also due to the high cost of lung cancer therapeutics. Some of the alternative therapeutics include mind and body medicines, biology-based practices, energy work, and whole medical systems.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/470096
Further, the report states that the growing popularity of alternative therapeutics are expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking for alternative therapeutics. The increased demand for these therapies is also due to the high cost of lung cancer therapeutics. Some of the alternative therapeutics include mind and body medicines, biology-based practices, energy work, and whole medical systems.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/470096
About Lung Cancer Therapeutics
Lung cancer is
a common cause of mortality and morbidity in both developed and developing
countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers.
Lung cancer can be categorized into two major types, namely NSCLC and SCLC.
NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of
the total diagnosed cases. It grows and spreads quite slowly.
Technavios analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• F. Hofmann-La Roche
• Eli Lilly
• AstraZeneca
• Pfizer
• Celgene
Other prominent vendors
• Abbvie
• Aetna
• Agennix
• Allergan
• Amgen
• ARIAD Pharmaceuticals
• Astellas Pharma
• Betta Pharmaceuticals
• BeyondSpring Pharmaceuticals
• BioNumerik Pharmaceuticals
• Boehringer Ingelheim
• Boston Biomedical
• Bristol-Myers Squibb
• Celldex
• CTI BioPharma
• Eisai
• GlaxoSmithKline
• GTx
• Helsinn
• Hutchison Medipharma
• Ionis Pharmaceuticals
• Kadmon Corporation
• MabVax
• Merck
• Novartis
• NovaRx Corporation
• OncoGeneX
• Ono Pharmaceutical
• OSE Immunotherapeutics
• OSI Pharmaceuticals
• Peregrine
• PharmaMar
• Pierre Fabre
• Qiagen
• Recombio
• Samsung Bioepis
• Sanofi
• SFJ Pharmaceuticals
• Spectrum Pharmaceuticals
• Sumitomo Dainippon Pharma
• Synta
• Takeda Pharmaceuticals
• Teva Pharmaceutical
• Xcovery
Market driver
• Growing demand for targeted therapies
• For a full, detailed list, view our report
Market challenge
• Growing popularity of alternative therapeutics
• For a full, detailed list, view our report
Market trend
• Emergence of nanomedicine platform for the treatment of lung cancer
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Technavios analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• F. Hofmann-La Roche
• Eli Lilly
• AstraZeneca
• Pfizer
• Celgene
Other prominent vendors
• Abbvie
• Aetna
• Agennix
• Allergan
• Amgen
• ARIAD Pharmaceuticals
• Astellas Pharma
• Betta Pharmaceuticals
• BeyondSpring Pharmaceuticals
• BioNumerik Pharmaceuticals
• Boehringer Ingelheim
• Boston Biomedical
• Bristol-Myers Squibb
• Celldex
• CTI BioPharma
• Eisai
• GlaxoSmithKline
• GTx
• Helsinn
• Hutchison Medipharma
• Ionis Pharmaceuticals
• Kadmon Corporation
• MabVax
• Merck
• Novartis
• NovaRx Corporation
• OncoGeneX
• Ono Pharmaceutical
• OSE Immunotherapeutics
• OSI Pharmaceuticals
• Peregrine
• PharmaMar
• Pierre Fabre
• Qiagen
• Recombio
• Samsung Bioepis
• Sanofi
• SFJ Pharmaceuticals
• Spectrum Pharmaceuticals
• Sumitomo Dainippon Pharma
• Synta
• Takeda Pharmaceuticals
• Teva Pharmaceutical
• Xcovery
Market driver
• Growing demand for targeted therapies
• For a full, detailed list, view our report
Market challenge
• Growing popularity of alternative therapeutics
• For a full, detailed list, view our report
Market trend
• Emergence of nanomedicine platform for the treatment of lung cancer
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Table
of content: https://marketreportscenter.com/reports/470096/global-lung-cancer-therapeutics-market-2016-2020#toc
About
Us:
Market Reports Center is an e-commerce
platform obliging the needs of knowledge workers, experts, professionals who
are subject to market research information for their work, or to make strategic
business decisions. Market Reports Center’s team consistently works to update
and extend our existing repository of market research reports by partnering
with new publishers and adding their studies to our website.
Contact us for more details:
Sam
Collins
Market Reports Center
Phone
No: 1-646-883-3044 (US)
Web - https://marketreportscenter.com
No comments:
Post a Comment